Indoco Remedies Gets USFDA Pre-Approval Inspection Cleared At Chhatrapati Sambhaji Nagar
Indoco Remedies Limited announced the successful completion of a US FDA pre-approval inspection at its testing facility in Chhatrapati Sambhaji Nagar with zero Form 483 observations. The three-day inspection conducted from April 08-10, 2026, confirms the facility's compliance with US FDA standards and current good manufacturing practices.
*this image is generated using AI for illustrative purposes only.
Indoco Remedies Limited has successfully completed a US Food and Drug Administration (US FDA) pre-approval inspection at its testing facility in Chhatrapati Sambhaji Nagar (Aurangabad) with zero Form 483 observations. The company announced this development to stock exchanges on April 13, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Inspection Details
The US FDA conducted the pre-approval inspection over a three-day period, providing a comprehensive assessment of the facility's compliance standards.
| Parameter: | Details |
|---|---|
| Inspection Period: | April 08, 2026 to April 10, 2026 |
| Facility Location: | Chhatrapati Sambhaji Nagar (Aurangabad) |
| Inspection Type: | Pre-Approval Inspection |
| Form 483 Observations: | Zero |
| Regulatory Authority: | US Food and Drug Administration |
Regulatory Significance
The completion of the inspection with zero Form 483 observations indicates that the testing facility meets US FDA standards without any regulatory concerns. Form 483 observations typically highlight deficiencies or areas requiring corrective action during FDA inspections. The absence of such observations demonstrates the facility's compliance with current good manufacturing practices and regulatory requirements.
Corporate Communication
The announcement was made through a formal communication to both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited. The disclosure was signed by Ramanathan Hariharan, Company Secretary & Head Legal, ensuring proper regulatory compliance and transparency with stakeholders.
This successful inspection outcome reinforces the company's commitment to maintaining high-quality standards at its manufacturing and testing facilities, particularly for products intended for the US market.
Historical Stock Returns for Indoco Remedies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.06% | +15.17% | +11.10% | -26.54% | -6.60% | -27.23% |
What specific drug products is Indoco Remedies seeking FDA approval for from this Aurangabad facility?
How might this successful inspection impact Indoco's timeline for launching new products in the US market?
Will this FDA clearance enable Indoco to expand its manufacturing capacity or pursue additional ANDA filings?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
